TGFB1 and pulmonary fibrosis: Several mechanisms may contribute to the therapeutic effects of BMSCs for early pulmonary fibrosis, such as inhibition of TGF-β-smad2/3 pathway and reduced expression of matrix metalloproteinase- (MMP-) 2, 9, and 13 [43, 44].